Abiraterone acetate (AA) in patients with metastatic castration-resistant prostate cancer (MCRPC) after docetaxel chemotherapy: Multicentric experience of Anatolian Society of Medical Oncology

Demirci, UmutOflazoglu, UtkuKodaz, HilmiCiltas, AydinKefeli, UmutAkyol, MuratOzturk, Banu2024-06-122024-06-1220140732-183X1527-7755https://doi.org/10.1200/jco.2014.32.15_suppl.e16094https://hdl.handle.net/20.500.14551/2591850th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -- MAY 30-JUN 03, 2014 -- Chicago, IL[Abstract Not Available]en10.1200/jco.2014.32.15_suppl.e16094info:eu-repo/semantics/closedAccess[No Keywords]Abiraterone acetate (AA) in patients with metastatic castration-resistant prostate cancer (MCRPC) after docetaxel chemotherapy: Multicentric experience of Anatolian Society of Medical OncologyConference Object3215Q1WOS:000358613200846